EVX-101 is a unique and proprietary oral slow-release formulation of 5-hydroxytryptophan (5-HTP) and low-dose carbidopa.
Initially, EVX-101 will be developed as a first-choice adjunctive treatment in depressed patients responding inadequately to conventional SSRI/SNRI antidepressants.
EVX-101 is a new chemical entity (NCE). Yet the development of EVX-101 is uniquely de-risked. The therapeutic mechanism is to elevate extracellular serotonin beyond the effect of conventional SSRI/SNRI antidepressants. This mechanism enjoys human proof-of-concept for efficacy and safety.
EVX-101 will be developed and marketed as an FDA-approved prescription medication.